A Clinical Study to Evaluate Safety, Tolerability and Pharmacokinetics of SV001 in Chinese Healthy Adult Volunteers.

Inclusion Criteria: 1. Subjects must fully understand the purpose, characteristics, methods and possible adverse reactions of the trial, volunteer as a subject, and sign the Informed Consent Form; 2. Subjects must have a Body Mass Index in the range of 19\~26 kg/m2, with males weighted not less than 50 kg, and females weighted not less than 45 kg; 3. Subjects must be in good health as judged by the investigator. 4. Reliable contraception must be assured during and for some time after the trial. Exclusion Criteria: 1. Subjects with a history of drug or other substance anaphylaxis; 2. Subjects with respiratory symptoms or abnormal respiratory tract; 3. Subjects currently having an oral disease that the investigator judged may affect use of the trial drug and devices; 4. Subjects with other diseases or factors with abnormal clinical manifestations; 5. Subjects having a history of drug abuse in the past or having used narcotics in the period prior to screening, or having a positive result in urine narcotics test at baseline period; 6. Subjects who smoked more than 5 cigarettes a day in the period before screening; 7. Subjects who consumed more than 14 units of alcohol per week in the period prior to screening, or who is positive in breath alcohol test at baseline period; 8. Subjects who have suffered a clinically significant severe disease or undergone major surgical operations within a certain period of time prior to receiving the investigational drug, or who are expected to require major operations during the clinical trial; 9. Subjects who used other drugs within a certain period of time before receiving the investigational drug; 10. Screening period: FEV1≤80% predicted value or FVC≤80% predicted value; 11. Subjects who have antibody positive for Human Immunodeficiency Virus, Hepatitis B surface antigen, Hepatitis C or Treponema Pallidum. 12. Subjects who have difficulty in venous blood collection or have a history of acupuncture syncope and blood phobia; 13. Female subjects who are tested positive for pregnancy during the screening or baseline period or are in lactation period; 14. Subjects who have participated in other drug clinical trials and used other drugs in clinical trials within a certain period of time before receiving the investigational drug; 15. Subjects who have a history of blood donation or blood loss of more than 400 mL in the period prior to screening; 16. Any other status in which the investigator deems inappropriate to participate in the present study.